Early COVID-19 Tests Scrutinized in CDC Internal Investigation
Early batches of COVID-19 tests from the CDC exhibited false positive reactivity of negative controls due to flaws in the design and components of assays.
Read MorePosted by Andy Lundin | Dec 17, 2021 | Covid 19, Immunoassay Reagents & test Kits |
Early batches of COVID-19 tests from the CDC exhibited false positive reactivity of negative controls due to flaws in the design and components of assays.
Read MorePosted by Andy Lundin | Dec 17, 2021 | Covid 19, Diagnostic Technologies |
Researchers developed an artificial intelligence (AI) model that can diagnose COVID-19, while also preserving the privacy of patient data.
Read MorePosted by Andy Lundin | Dec 16, 2021 | Diabetes & Metabolic Diseases |
The FDA Program will provide Life Science Biosensor Diagnostics with a path toward regulatory approval for its non-invasive, real-time saliva glucose test.
Read MorePosted by Andy Lundin | Dec 16, 2021 | Covid 19, Rapid Assays |
LumiraDx’s SARS-CoV-2 assay will now offer a self-collected COVID-19 nasal specimen collection kit through a new partnership with Audere.
Read MorePosted by Chris Wolski | Dec 16, 2021 | Covid 19 |
Researchers have tested a breathalyzer, known as the Bubbler, that relies on viral RNA detection to diagnose SARS-CoV-2.
Read More